Atopic Dermatitis & Psoriasis
Inflammatory skin diseases are common and associated with highly visible signs (redness, dryness, scaling), psychosocial burden, and systemic comorbidities. Recent scientific advances have improved our understanding of inflammatory skin diseases and have led to many new treatment options, some already FDA-approved and other emerging. However, not all treatments are approved for use in children and questions remain about the long-term effects of these treatments, including side effects and impact on disease course and risk of associated disorders.
The Goals of the Atopic Dermatitis and Psoriasis Focused Study Group are to define and address unmet research needs in inflammatory skin diseases, to discover new therapies, and to advance our understanding of biomarkers, genetic influences, and disease comorbidities.
Chairs
The AD & Psoriasis Focused Study Group is co-chaired by Amy Paller, MD from Northwestern University, and Minnelly Luu, MD from the University of Southern California, Los Angeles.
Links
Studies
- A Pilot Study to Assess the Impact of a Validated Illustrated Eczema Action Plan on Pediatric Patients
- Antibiotic/Antimicrobial Resistance in Atopic Dermatitis
- Atopic Dermatitis: An Assessment of Lesional Morphology by Race/Ethnicity
- Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
- Characterization of Non-Alcoholic Fatty Liver in Pediatric Psoriasis
Publications
Croce, Emily, et al. “Validation of remote atopic dermatitis severity assessment with the Eczema Area and Severity Ondex in children using caregiver-provided photos and videos” Pediatric Dermatology (2022).
Croce, Emily, et al. “Caregiver Preferences and Barriers Toward Accessing Pediatric Dermatology Care for Childhood Atopic Dermatitis” Journal of Pediatric Healthcare (2022).
Rustad, Andrea, et al. “Incorporating joint pain screening into the pediatric dermatologic examination” Pediatric Dermatology (2021).
Bronckers, Inge, et al. “A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents” JAMA Dermatology (2020).
Siegfried, Elaine C., et al. “Developing drugs for treatment of atopic dermatitis in children (≥ 3 months to< 18 years of age): Draft guidance for industry.” Pediatric Dermatology 35.3 (2018): 303-322.
Singer, Hannah M., et al. “Texting atopic dermatitis patients to optimize learning and eczema area and severity index scores: A pilot randomized control trial.” Pediatric Dermatology 35.4 (2018): 453-457.
Siegfried, Elaine C., et al. “Optimizing Clinical Trials for Atopic Dermatitis in Children.” Journal of Investigative Dermatology 137.6 (2017): 1363-1364.
Bronckers, Inge MGJ, et al. “Safety of systemic agents for the treatment of pediatric psoriasis.” JAMA Dermatology 153.11 (2017): 1147-1157.
Osier, Emily, et al. “Pediatric Psoriasis Comorbidity Screening Guidelines.” JAMA Dermatology 153.7 (2017): 698-704.
Totri, Christine R., et al. “Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.” Journal of the American Academy of Dermatology 76.2 (2017): 281-285.
Resources
Pediatric Psoriasis Comorbidity Screening Guidelines
The Rapid Joint Examination Technique (R-JET) is a screening examination for arthritis that can be incorporated into the routine dermatological examination when patients complain of joint discomfort, especially those with skin disorders that are known to be associated with arthritis.
Active Member Locations
Get involved!
Send us an email to get connected to the AD & Psoriasis group or to learn more.